Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Israeli strike kills 4 civilians in southern Lebanon, state media saysCould your doctor be GOOGLING you? Calls for crack down on unspoken habitDAN HODGES: How the plot against Rishi really fell apartShocking moment man spits towards proStudent killed outside Wisconsin school had pellet rifle, police saySavers withdraw £5bn from current accounts in bid for better interest ratesTilda Swinton, 63, shows off her unique style in rare outing with longWarren Buffett's company faces lawsuit over shareholder proposalDunlap declared PGA Tour Champions winner after rain washes out final roundLemi Berhanu Hayle wins Prague international marathon, Bedatu Hirpa Badane claims women's race
2.6935s , 5761.0625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Canvas news portal